Investigational Blood Test Shows Promise in Detecting Early-Stage Pancreatic Cancer
Researchers at City of Hope, a prominent cancer research and treatment institution, have helped develop a novel investigational liquid biopsy designed to identify pancreatic cancer during its earliest, most treatable phases. The findings were detailed in a large, international study published in Nature Medicine.
Pancreatic cancer continues to present significant clinical challenges, holding the lowest survival rates among major malignancies. Approximately 90% of patients receive a diagnosis only after the disease has advanced and spread throughout the body, leaving a narrow window for curative interventions. The five-year survival rate for the condition currently sits at roughly 14%. Investigators hope that blood-based diagnostic tools can shift this paradigm by catching the disease before clinical symptoms manifest.
The experimental diagnostic tool, known as PANXEON, evaluates blood samples for three distinct biological markers rather than relying on a single signal. The test measures circulating microRNAs, exosomal microRNAs, and a specific protein called CA19-9. Artificial intelligence algorithms then process these three distinct measurements, synthesizing them into a single comprehensive risk score for the patient.
To evaluate the efficacy of the liquid biopsy in diverse clinical environments, researchers tested the approach on nearly 1,800 patients across the United States, Europe, and Asia. According to the study results, the blood test successfully identified stage 1 and stage 2 pancreatic cancer 87% of the time. Furthermore, the false-positive rate remained low, registering at 3% among low-risk populations and 16% within high-risk groups.
Dr. Ajay Goel, senior author of the study and chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope, noted that most individual biomarkers provide only a limited perspective. By amalgamating multiple biological signals, researchers can achieve a much clearer picture of biological activity occurring within the pancreas. Dr. Goel emphasized that the tool is not intended to replace standard imaging techniques, but rather to assist clinicians in pinpointing high-risk individuals who require more rigorous diagnostic evaluation.
An encouraging aspect of the investigation involved the detection of high-grade dysplasia, an advanced precancerous state often characterized as stage 0 pancreatic cancer. The liquid biopsy identified this precancerous condition in more than 64% of cases. Medical professionals suggest that this capability could greatly assist in determining which pancreatic cysts demand active clinical monitoring or therapeutic intervention before invasive malignancies have the opportunity to develop.
Individuals who stand to benefit most from advancements in early detection include those with hereditary genetic risks, a documented family history of pancreatic cancer, chronic pancreatitis, or existing pancreatic cysts. Current surveillance protocols for these high-risk groups often rely on imaging and other methods that can be invasive and costly while offering limited efficacy for catching the disease in its infancy.
Researchers indicate that ongoing efforts in early detection are critical to improving patient outcomes. Organizations such as City of Hope continue to investigate multi-marker diagnostics alongside targeted therapies and specialized vaccines to expand clinical options for patients facing pancreatic malignancies.
Source: News-Medical.net
